A Novel CYP2E1 Inhibitor, 4‐Methyl‐5‐Acetylthiazole (Q11), Alleviates Obesity Via Modulating Adipose Inflammation and Mitochondrial Dysfunction
Advanced Science · 2026-02 · 13 (10)
DOI: 10.1002/advs.202515315 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, online erschienen am 20.12.2025. Verfasst von Jinhuan Qiu und 10 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Clinical Pharmacology, School of Basic Medical Sciences, Zhengzhou University, Zhengzhou, China. Hauptthemen laut MEDLINE: Obesity, Mitochondria, Cytochrome P-450 CYP2E1, Inflammation. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 62 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Obesity is a major global health challenge characterized by chronic low‐grade inflammation and impaired mitochondrial homeostasis. Although cytochrome P450 2E1 (CYP2E1) is implicated in oxidative stress and inflammatory signaling, its contribution to adipocyte dysfunction during obesity remains insufficiently defined. Here, we evaluate the functional role of CYP2E1 in obesity and the therapeutic potential of a highly selective CYP2E1 inhibitor, 4‐methyl‐5‐acetylthiazole (Q11). High‐fat diet‐induced obese mice exhibited markedly elevated CYP2E1 expression and activity, which positively correlated with increased adiposity, hepatic steatosis, and mitochondrial dysfunction. Pharmacological inhibition of CYP2E1 by Q11 significantly attenuated body weight gain, improved hepatic lipid accumulation, and reduced inflammatory responses without affecting food intake, suggesting that its metabolic benefits are mediated through enhanced energy expenditure. Mechanistically, Q11 restored mitochondrial integrity by increasing oxygen consumption, normalizing membrane potential, promoting mitochondrial biogenesis, and improving fusion dynamics, accompanied by activation of the AMP‐activated protein kinase/peroxisome proliferator‐activated receptor‐gamma coactivator 1‐alpha pathway. Collectively, these findings identify CYP2E1 as a previously unrecognized regulator of obesity‐associated metabolic dysfunction and establish Q11 as a promising therapeutic candidate that concurrently suppresses inflammation and reinstates mitochondrial homeostasis. This work provides a mechanistic and translational foundation for targeting CYP2E1 in obesity and related metabolic disorders.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Clinical Pharmacology, School of Basic Medical Sciences, Zhengzhou University, Zhengzhou, China.
ORCID-Profile: Hailing Qiao
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Qiu, J., Gao, L., Wang, L., Wang, X., Jia, L., Deng, M., Tang, L., Wen, Q., Gao, N., Xu, H., & Qiao, H. (2026). A Novel CYP2E1 Inhibitor, 4‐Methyl‐5‐Acetylthiazole (Q11), Alleviates Obesity Via Modulating Adipose Inflammation and Mitochondrial Dysfunction. Advanced Science, 13(10). https://doi.org/10.1002/advs.202515315
Vancouver
Qiu J, Gao L, Wang L, Wang X, Jia L, Deng M, et al. A Novel CYP2E1 Inhibitor, 4‐Methyl‐5‐Acetylthiazole (Q11), Alleviates Obesity Via Modulating Adipose Inflammation and Mitochondrial Dysfunction. Advanced Science. 2026;13(10). doi:10.1002/advs.202515315
BibTeX
@article{Qiu2026,
author = {Qiu, Jinhuan and Gao, Liyuan and Wang, Liyang and Wang, Xueke and Jia, Lin and Deng, Mengyan and Tang, Liming and Wen, Qiang and Gao, Na and Xu, Haiwei and Qiao, Hailing},
title = {A Novel CYP2E1 Inhibitor, 4‐Methyl‐5‐Acetylthiazole (Q11), Alleviates Obesity Via Modulating Adipose Inflammation and Mitochondrial Dysfunction},
journal = {Advanced Science},
year = {2026},
volume = {13},
number = {10},
doi = {10.1002/advs.202515315}
}
EUVIMED